Inhibrx Biosciences (INBX) Capital Expenditures (2023 - 2025)
Inhibrx Biosciences (INBX) reported Capital Expenditures of $10000.0 for Q3 2025, down 99.58% year-over-year from $2.4 million in Q3 2024, and down 52.38% quarter-over-quarter from $21000.0 in Q2 2025.
Inhibrx Biosciences (INBX) Capital Expenditures (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Capital Expenditures data on file, last reported at $10000.0 in Q3 2025.
- Capital Expenditures for Q3 2025 came in at $10000.0, down 99.58% year-over-year; the trailing twelve-month figure through Dec 2025 was $31000.0 (down 98.81% YoY), and the FY2025 annual result was $31000.0, down 98.81% from the prior year.
- Capital Expenditures slipped to $10000.0 in Q3 2025 per INBX's latest filing, from $21000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $3.4 million in Q4 2023 and troughed at -$100000.0 in Q2 2024.
- A 3-year average of $860125.0 and a median of $164000.0 in 2024 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures soared 192.73% in 2024, then slumped 99.58% in 2025.
- A 3-year view of Capital Expenditures shows it stood at $3.4 million in 2023, then plunged by 99.54% to $16000.0 in 2024, then tumbled by 37.5% to $10000.0 in 2025.
- Business Quant data shows INBX's Capital Expenditures at $10000.0 in Q3 2025, $21000.0 in Q2 2025, and $16000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Inhibrx Biosciences | 186.16 Mn | 186.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 10,000.00 |
| Sep 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 21,000.00 |
| Jun 30, 2025 | 21,000.00 |
| Dec 31, 2024 | 16,000.00 |
| Dec 31, 2024 | 16,000.00 |
| Sep 30, 2024 | 2.37 Mn |
| Sep 30, 2024 | 2.37 Mn |
| Jun 30, 2024 | -100,000.00 |
| Jun 30, 2024 | -100,000.00 |
| Mar 31, 2024 | 307,000.00 |
| Mar 31, 2024 | 307,000.00 |
| Dec 31, 2023 | 3.44 Mn |
| Dec 31, 2023 | 3.44 Mn |
| Sep 30, 2023 | 811,000.00 |
| Sep 30, 2023 | 811,000.00 |